Michael Lin Baum is a respected Southern California lawyer who engages as managing partner with Baum Hedlund Aristei & Goldman. Taking on major corporations, Michael Lin Baum has represented numerous plaintiffs in pharmaceutical drug catastrophe cases.
One area of focus centers on birth defects associated with the antidepressant Citalopram, which is marketed as Celexa. The selective serotonin reuptake inhibitor (SSRI) is prescribed in treating conditions such as premenstrual dysphoric disorder, obsessive compulsive disorder, and attention deficit hyperactivity disorder. Produced by Forest Laboratories, Celexa is marketed alongside the pharmacologically similar, but more potent SSRI Lexapro.
Celexa was initially classified by the US Food and Drug Administration (FDA) as a category C drug that had not been tested on pregnant women, but which had harmful side effects demonstrated through animal testing on fetuses. In 2005, the FDA issued a Public Health Advisory focused on SSRI antidepressants, and the following year a specific warning was issued against Celexa.
In particular, newborns are more likely to be born with life-threatening persistent pulmonary hypertension. This issue is the focus of Baum Hedlund Aristei & Goldman’s work concerning the link between Celexa prescriptions and birth defects.
You must be logged in to post a comment.